Compare Roblox Corp (RBLX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Roblox Corp trades at $48.09 (market cap $32.52B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Roblox Corp is far larger — about 3.2× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 93 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| RBLX | XBI | |
|---|---|---|
Market Cap | $32.52B | $10.11B |
Volume | 14,552,045 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $138.56 | $169.55 |
52-Week Low | $35.54 | $104.99 |
Typical Hold Time | 93 Days | 38 Days |
Enterprise Value | $31.34B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $45.53, down 1.9% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to demonstrate strong revenue growth, reaching $4.89 billion in 2025, but remains unprofitable with a net income margin of -17.61%. Recent analyst downgrades from Jefferies highlight concerns about bookings growth, creating mixed sentiment around the stock's near-term prospects.
While Roblox shows impressive revenue expansion and strong cash flow generation, persistent losses and high valuation metrics present significant risks. The stock faces headwinds from technical weakness and analyst skepticism, though long-term growth potential in the gaming platform remains intact. Investors must weigh the company's growth trajectory against ongoing profitability challenges.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
